Global Smallpox Treatment Market

Global Smallpox Treatment Market

Global Smallpox Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.

Smallpox is a highly contagious and often severe infectious disease caused by the variola virus. It is unique to humans and has been responsible for significant morbidity and mortality. Smallpox is primarily transmitted from person to person through respiratory droplets released during close contact or through direct contact with the virus in respiratory secretions, saliva, or skin lesions.

Smallpox vaccination, using the vaccinia virus is highly effective in preventing smallpox. It can cause a hard, blistering rash that often leads to disfiguring scars. About 1 in 3 people who got smallpox died from the disease.

Market Dynamics

Increasing drug approvals

The increasing drug approval for smallpoxpox treatment acts as a significant driver for market growth. For instance, in May 2021, the Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TpoYY (tecovirimat) for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients.

Additionally, in September 2019, Bavarian Nordic A/S declared that the U.S. Food and Drug Administration (FDA) has approved JYNNEOS (MVA-BN) for the prevention of smallpox and monkeypox disease in adults 18 years of age and older. Furthermore, significant growth drivers such as the rising awareness regarding smallpox, and government funding are expected to drive the market in the forecast period.

Side effects associated with smallpox vaccination

Common side effects after vaccination include pain, redness and swelling at the site of vaccination. It can also lead to systemic reactions like fever, headache, and uneasiness. Other side effects also include heart inflammation (myocarditis), and inflammation of the lining of the heart (pericarditis). Thus, the above factors can hamper the market growth.

Segment Analysis

The global smallpox treatment market is segmented based on treatment, route of administration, distribution channel and region.

The antiviral medication segment accounted for approximately 54.7% of the market share

The antiviral medication segment is expected to hold the largest market share over the period forecast due to the increasing number of product approvals. Antiviral medications like Tecovirimat and Brincidofovir are used to treat smallpox.

Tecovirimat (TPOYY) is an antiviral medication that has been developed for the treatment of human smallpox. It is a small-molecule compound and a first-in-class drug specifically designed to inhibit the replication of orthopoxviruses, including the variola virus, which causes smallpox.

Additionally, Brincidofovir is an antiviral medication that belongs to the class of drugs known as nucleotide analogs. It is developed for the treatment of certain viral infections, particularly those caused by double-stranded DNA viruses.

Geographical Analysis

North America is expected to hold a significant position in the global smallpox treatment market share

The global smallpox treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising research and development, government initiatives, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, In June 2021, the FDA approved brincidofovir (brand name TEMBEXA) for the treatment of smallpox. Brincidofovir's effectiveness against smallpox was established with in vitro studies using related orthopoxviruses as well as variola.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global smallpox treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, drug launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the smallpox treatment market is expected to be moderately affected over the forecast period.

Market Segmentation

By Treatment
• Antiviral Medication
Tecovirimat (TpoYY)
Brincidofovir (Tembexa)
• Vaccines
ACAM2000
APSV
MVA-BN

By Route of Administration
• Oral
• Parenteral

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include SIGA Technologies Inc., Bavarian Nordic A/S, Emergent Biosolutions Inc., Sanofi S.A, Pfizer Inc., and Chimerix Inc. among others.

Why Purchase the Report?
• To visualize the global smallpox treatment market segmentation based on treatment, route of administration, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global smallpox market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global smallpox treatment market report would provide approximately 58 tables, 58 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies